Amneal Pharmaceuticals launches authorized generic esomeprazole strontium delayed-release capsules

BRIDGEWATER, N.J. — Amneal Pharmaceuticals has launched an authorized generic version of a recently launched drug for gastroesophageal reflux disease, the company said Monday.

Amneal announced the launch of esomeprazole strontium delayed-release capsules in the 49.3-mg strength. The drug's active ingredient is of the same active moiety as the one in AstraZeneca's Nexium (esomeprazole magnesium), but in a different salt form. Amneals product is a version of the recently launched branded esomeprazole strontium, for which it is partnering with South Korea-based Hanmi Pharmaceutical Co. The branded product was launched last month, and the companies received a favorable ruling in the U.S. Court of Appeals in a lawsuit filed against them by AstraZeneca. Authorized generics are branded drugs launched at a discounted price, usually under partnerships between the original branded drug makers and third-party companies.

"Introducing generic esomeprazole strontium offers a new, cost-effective treatment option for adult GERD sufferers," Amneal chairman and CEO Chirag Patel said. "It's another example of how Amneal's innovative growth strategy has helped to bring economical generic medications to market and benefit all stakeholders in the healthcare equation - patients, prescribers, pharmacists and payers."